EPO and tauopathy: Along with our recently published brief supplementary study of assessing the effect of JM4 treatment on PS19 mice noninvasively using bioluminescence imaging of glia fibrillary acid protein [36], this is the first study showing beneficial effects of EPO or its derivatives in a mouse model of tauopathy.